Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Outcome
% Chance
Outcome
%Chance
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
Will an AI-Designed Drug Receive Regulatory Approval by 2030?
By placing order, you agree to Terms & Conditions
Resolution Criteria
This market resolves to Yes if, on or before December 31, 2030, a drug primarily designed using artificial intelligence is granted full regulatory approval (i.e., full marketing authorization; emergency use authorizations (EUA), conditional approvals, or expanded access do not count) by one of the following regulatory agencies: FDA (US), EMA (EU centralized authorization), MHRA (UK), PMDA (Japan), or NMPA (China) for human use.
“AI-designed” means that, in official company materials and/or regulatory documentation, the drug is explicitly described as having been primarily designed or discovered using AI, where AI is credited with either:
- generating the initial lead molecular structure (or de novo scaffold) that became the approved active ingredient, or
- identifying the biological target or binding hypothesis that the approved drug acts on.
Subsequent human-led optimization and testing does not disqualify the drug.
At least one credible report or official announcement of such an approval by 2030 is required for a Yes resolution. If no such drug is approved by then, the market resolves to No.
News
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA - BioSpace
Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Deramiocel (CAP-1002) BLA for Duchenne muscular dystrophy from August 22, 2026 to November 22, 2026, after Capricor submitted an amendment with 24-month HOPE-3 follow-up data and robustness analyses aiming to refine the indication to upper limb function, which the FDA accepted for review as a major amendment.
Why AI-Driven Drug Discovery Is Becoming Pharma’s Next Big Bet | Collector: Breaking News, World News, Trending Stories
AI-driven drug discovery is poised to dramatically cut preclinical R&D costs and timelines (potentially by up to 70%), but its ultimate success hinges on delivering safe, effective medicines to patients.
FDA is drafting GenAI device guidance, digital health chief says | Pivot News
The FDA, via Digital Health Center of Excellence head Rick Abramson, is developing formal policy guidance on regulating generative AI medical devices, planning both broad overarching guidance and narrower, specialty documents on complex topics, though no publication timeline was provided.
AI Drug Repurposing Market Growth, Driving Factors, Strategies,...
The article reports that the AI drug repurposing market is projected to grow from USD 1.5 billion in 2026 to USD 8.8 billion by 2036 (19.4% CAGR), driven by factors such as known-compound reuse and evidence graph matching, with small molecules and oncology leading segments and the USA as a top market, while highlighting strategic implications for pharma teams, platform vendors, and investors.
FDA Seeks Public Feedback On Regulatory Approach For Generative AI-Enabled Medical Devices - Healthcare - United States
The FDA has released a discussion paper proposing a two-axis risk framework and a competency-based premarket evaluation for generative AI-enabled medical devices, seeks public comments by October 19, 2026, and invites feedback on issues like foundation models, postmarket monitoring, and regulatory responsibility across the supply chain.
Vinal PatelAI poised to cut drug discovery costs by 70%, survey finds · PulseAugur
AI could cut preclinical drug discovery costs and timelines by up to 70%, according to a TD Cowen survey, as computational methods become essential alongside lab work and policy shifts reducing animal testing accelerate adoption.
STAT+: FDA digital health leader promises generative AI regulatory guidance is coming – RamaOnHealthcare
The FDA is developing a regulatory plan for medical devices that use generative AI and will publish documents outlining its policies, signaling a move toward a competency-based, future-guided approach under the Digital Health Center of Excellence.
RamaOnHealthcareFDA's PreCheck Pilot Program: Speeding Up Review of New Manufacturing Facilities (2026)
The FDA’s PreCheck pilot accelerates review of new manufacturing facilities by up to 14 months, starting with Eli Lilly, Regeneron, and five others, focusing on biologics and gene therapies to boost domestic production and faster access to therapies, while raising concerns about regulatory authority, equity, and potential shifts in industry dynamics.
NCTY - US Stocks Welcome AI Pharmaceutical Unicorn, Chinese Capital Bets 6 Years On
The article reports that NYB Holdings and RFAI progressed toward a merger valuing NYB at about $1.5 billion, with a projected post-merger equity value near $12 billion and a Nasdaq listing under NYB, while NineCity (The9) stands to gain roughly $1.8–$1.92 billion from a ~15–16% stake, reflecting a substantial, AI-driven drug development platform and a multi-year, China-linked investment pivot.
Overcoming the Limitations in siRNA Drug Development: XtalPi’s AI-Powered Generative siRNA Therapeutics Design Platform - Adrienne Monson - Lifestyle
Kodexia™, XtalPi’s AI-powered platform, integrates generative AI and first-principles RNA biology to co-optimize siRNA sequence design and chemical modifications, improve in vitro/in vivo silencing, enhance durability and safety, optimize delivery and IP differentiation, and accelerate lead candidate identification while expanding the exploration of differentiated designs beyond traditional IP constraints.
Written By: EIN Presswire